CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.
- DOI
- 10.1016/s2352-3026(26)00192-4
- Published
- 2026 Sep
- Container
- The Lancet. Haematology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2352-3026-26-00192-4,
title = {CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.},
author = {Kersten MJ and Kuipers MT and Mutsaers PGNJ and Willems E and Saevels K and Dreyling M and Jacobson C and Bishop MR and Zandvliet M and Milatos S and Lobetti-Bodoni C and Blum S and Van Hoorde K and Desai J and Acciarri L and Pont MJ and van Muyden A and Fasan O and Vermaat JSP and Anguille S},
year = {2026},
journal = {The Lancet. Haematology},
doi = {10.1016/s2352-3026(26)00192-4},
url = {https://doi.org/10.1016/s2352-3026(26)00192-4}
}RIS
TY - JOUR TI - CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study. AU - Kersten MJ AU - Kuipers MT AU - Mutsaers PGNJ AU - Willems E AU - Saevels K AU - Dreyling M AU - Jacobson C AU - Bishop MR AU - Zandvliet M AU - Milatos S AU - Lobetti-Bodoni C AU - Blum S AU - Van Hoorde K AU - Desai J AU - Acciarri L AU - Pont MJ AU - van Muyden A AU - Fasan O AU - Vermaat JSP AU - Anguille S PY - 2026 JO - The Lancet. Haematology DO - 10.1016/s2352-3026(26)00192-4 UR - https://doi.org/10.1016/s2352-3026(26)00192-4 ER -
APA
MJ, K., MT, K., PGNJ, M., E, W., K, S., M, D., C, J., MR, B., M, Z., S, M., C, L., S, B., K, V. H., J, D., L, A., MJ, P., A, V. M., O, F., JSP, V., & S, A. (2026). CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.. The Lancet. Haematology. https://doi.org/10.1016/s2352-3026(26)00192-4
Source records
- pubmed · retrieved 2026-09-26T07:44:24.049Z